Evaluation of the RSR 3 screen ICA™ and 2 screen ICA™ as screening assays for type 1 diabetes in Sweden
(2022) In Acta Diabetologica 59(6). p.773-781- Abstract
Aim: The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). Methods: 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied. Results: 3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive... (More)
Aim: The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). Methods: 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied. Results: 3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls. Conclusion: 3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted.
(Less)
- author
- Törn, Carina LU ; Vaziri-Sani, Fariba LU ; Ramelius, Anita LU ; Elding Larsson, Helena LU ; Ivarsson, Sten Anders LU ; Amoroso, Marie ; Furmaniak, Jadwiga ; Powell, Michael and Smith, Bernard Rees
- organization
- publishing date
- 2022-02-26
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- GADA, IA-2A, IAA, Sensitivity, Specificity, ZnT8A
- in
- Acta Diabetologica
- volume
- 59
- issue
- 6
- pages
- 773 - 781
- publisher
- Springer
- external identifiers
-
- pmid:35220476
- scopus:85125288104
- ISSN
- 0940-5429
- DOI
- 10.1007/s00592-022-01856-5
- language
- English
- LU publication?
- yes
- id
- 7b464c83-ca32-442b-b166-994ad1fca645
- date added to LUP
- 2022-03-23 10:46:09
- date last changed
- 2024-09-29 07:06:48
@article{7b464c83-ca32-442b-b166-994ad1fca645, abstract = {{<p>Aim: The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). Methods: 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied. Results: 3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls. Conclusion: 3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted.</p>}}, author = {{Törn, Carina and Vaziri-Sani, Fariba and Ramelius, Anita and Elding Larsson, Helena and Ivarsson, Sten Anders and Amoroso, Marie and Furmaniak, Jadwiga and Powell, Michael and Smith, Bernard Rees}}, issn = {{0940-5429}}, keywords = {{GADA; IA-2A; IAA; Sensitivity; Specificity; ZnT8A}}, language = {{eng}}, month = {{02}}, number = {{6}}, pages = {{773--781}}, publisher = {{Springer}}, series = {{Acta Diabetologica}}, title = {{Evaluation of the RSR 3 screen ICA™ and 2 screen ICA™ as screening assays for type 1 diabetes in Sweden}}, url = {{http://dx.doi.org/10.1007/s00592-022-01856-5}}, doi = {{10.1007/s00592-022-01856-5}}, volume = {{59}}, year = {{2022}}, }